Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 13;5(1):e001206.
doi: 10.1136/bmjpo-2021-001206. eCollection 2021.

Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review

Eleanor Grace Dixon  1   2 , Charlotte Em Rugg-Gunn  2   3 , Vanessa Sellick  4 , Ian P Sinha  2   5 , Daniel B Hawcutt  2   6
Affiliations

Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review

Eleanor Grace Dixon et al. BMJ Paediatr Open. .

Abstract

Background: Asthma is the most common chronic condition of childhood. Leukotriene receptor antagonists (LTRAs) are included in international guidelines for children and young people (CYP), but there have been highly publicised concerns about potential adverse effects. The aim was to identify and understand the reported frequency of adverse drug reactions (ADRs) attributed to LTRAs in CYP with asthma.

Methods: Embase, MEDLINE, PubMed and CINAHL were searched up to October 2020. Reference lists of eligible papers were manually screened. Eligible studies identified adverse events attributed to an LTRA in individuals aged between 0 and 18 years diagnosed with asthma. Four different tools were used to assess risk of bias or quality of data to accommodate the papers assessed.

Results: The search identified 427 papers after deduplication; 15 were included (7 case reports, 7 case-controlled or cohort studies and 1 randomised control trial (RCT)). 7012 patients were recorded, of which 6853 received an LTRA. 13 papers examined the ADRs attributed to montelukast, one to pranlukast and one to unspecified LTRAs. After language standardisation, 48 ADRs were found, 20 of which were psychiatric disorders. Across all studies, the most commonly reported ADRs were 'anxiety', 'sleep disorders' and 'mood disorders'. The frequency of ADRs could be calculated in seven of the eight studies. Applying standardised frequency terms to the prospective studies and RCT, there were 14 'common' and 'uncommon' ADRs. 'Common' ADRs included 'agitation/hyperactivity/irritability/nervousness', 'aggression' and 'headache'. The case reports showed a similar pattern, describing 46 different ADRs experienced by a total of eight patients.

Conclusions: LTRAs have a wide range of suspected ADRs in CYP, predominantly gastrointestinal and neuropsychiatric disorders. Careful monitoring of CYP with asthma is required, both to assess and manage ADRs and to step treatment down when clinically stable.

Prospero registration number: CRD42020209627.

Keywords: pharmacology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: VS has close relationships with individuals and families who identify as being adversely affected by montelukast side effects.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferrante G, La Grutta S. The burden of pediatric asthma. Front Pediatr 2018;6:186. 10.3389/fped.2018.00186 - DOI - PMC - PubMed
    1. World Health Organisation . Asthma: World health organisation, 2020. Available: https://www.who.int/news-room/q-a-detail/asthma [Accessed 09 Sep 2020].
    1. Asthma UK . Asthma deaths in the UK, 2001-2016, 2021. Available: https://www.asthma.org.uk/support-us/campaigns/data-visualisations/#Deaths [Accessed 29 Jan 2021].
    1. Pharmaceutical Services Negotiating Committee . Essential facts, STATs and Quotes relating to asthma, 2020. Available: https://psnc.org.uk/services-commissioning/essential-facts-stats-and-quo..., everyclassroomintheUK.2018[updatedMay2018;cited202018/11/20]. Availablefrom:https://psnc.org.uk/services-commissioning/essential-facts-stats-and-quo..., everyclassroomtheUK [Accessed 18 Nov 20].
    1. Lundbäck B, Gibson J. Robert Loddenkemper YS, Gibson J, Lundbäck B, eds. Respiratory health and disease in Europe. In, 2013. - PubMed

Publication types

Substances